Carda Health and ACLM push virtual rehabilitation deeper into lifestyle medicine
Carda Health is extending its reach in virtual cardiac and pulmonary rehabilitation through a year-round partnership with the American College of Lifestyle Medicine, a move that places home-based chronic disease care squarely inside a broader lifestyle medicine strategy. The companies say the collaboration will center on education, research, clinician engagement, and wider access to evidence-based care delivered outside the traditional rehab setting.
The pairing matters because rehabilitation remains one of the clearest examples of a therapy that works well on paper but often fails in practice when patients cannot get to the clinic. Distance, transportation problems, work schedules, and caregiving responsibilities can all interfere with completion, and those gaps translate directly into missed recovery opportunities for patients with heart and lung disease. By moving monitored exercise and clinical support into the home, Carda’s model tries to close the distance between prescription and adherence.
Carda describes its program as combining one-on-one clinical support, live monitored exercise, and real-time vital measurements. In practical terms, that means rehabilitation is not reduced to an app or a passive video library; it is supervised, measured, and adjusted in real time. For patients recovering from cardiovascular or pulmonary disease, that structure is important because exertion has to be safe enough to sustain participation while still being intense enough to drive physiologic improvement.
Home-based care meets a national lifestyle medicine organization
ACLM’s role gives the partnership a different kind of weight. The organization has made lifestyle medicine a central part of its identity, and the collaboration ties virtual rehabilitation to a larger agenda focused on diet, movement, behavior change, and chronic disease management. Martin Tull, ACLM’s chief impact officer, framed the work around the burden that cardiovascular and other chronic diseases place on patients, families, and the health care system, and described the goal of expanding virtual access to the Ornish Program, an ACLM Lifestyle Medicine Certified Program.
That link to the Ornish Program is clinically significant because the program is built around intensive lifestyle change rather than a narrow procedural or pharmacologic intervention. Home-based delivery can lower one of the most persistent barriers in rehabilitation: the mismatch between what clinicians prescribe and what patients can realistically attend. When a therapy depends on repeated visits, convenience becomes a determinant of efficacy, not a trivial logistics issue.
The collaboration also includes educational programming, member resources, and the possibility of joint research pilots and demonstration projects. Carda will contribute webinars, podcasts, and other educational materials to ACLM’s member community, which suggests the partnership is intended to influence clinician behavior as much as patient access. In chronic disease care, provider familiarity can shape referral patterns, and referral patterns often shape whether rehabilitation is treated as a standard recovery step or an optional add-on.
A webinar and conference session anchor the launch
The first programming begins this fall with a November 4 webinar titled “Rehab Reimagined: Virtual Care’s Impact on Access and Outcomes.” The session is set to feature Dr. Dean Ornish, Haley Uher, who leads clinical exercise physiology at Carda Health, and Julie Stebbins, director of outpatient cardiology services at WellStar Health System. The discussion is expected to focus on the real-world consequences of virtual delivery, including access, outcomes, and the mechanics of delivery at home.
One sentence captures the practical edge of the model: the rehabilitation session happens where the patient already lives.
Carda will also participate in ACLM’s 2026 Lifestyle Medicine Conference in Orlando from November 8 to 11. DiFrancesco and Dr. Ornish are scheduled to lead a session titled “Undo It, At Home: How Virtual Care Is Taking Ornish’s Heart Disease Reversal Program to Everyone” on November 9. The session will cover the clinical foundation for intensive cardiac rehabilitation, completion rates, readmissions, and cost per patient, and will include an anonymized patient case.
Those topics point to the questions that matter most when home-based rehabilitation is compared with facility-based care. Completion rates can determine whether a program is merely available or actually used. Readmissions can show whether rehab changes downstream utilization. Cost per patient can decide whether payers and health systems view the model as sustainable or as another well-intended but fragile pilot.
Medicare coverage and the push to normalize virtual rehab
The partnership builds on a national arrangement Carda Health and Ornish Lifestyle Medicine announced earlier in the year, which delivers the Medicare-covered Intensive Cardiac Rehabilitation program in patients’ homes through Carda’s platform. That detail is especially relevant because Medicare coverage often determines whether a service moves from innovation to infrastructure. A program that exists only for self-pay patients may demonstrate feasibility; a covered benefit can change whether clinicians refer and whether patients follow through.
For patients with heart disease or pulmonary disease, the home setting can also reduce the friction that often undermines long-term engagement. Exercise tolerance, symptom monitoring, and medication adherence are all easier to reinforce when the care team can observe the patient over time rather than relying on occasional office follow-up. Real-time vitals collection adds another layer of safety, particularly for individuals who may be deconditioned or medically complex when rehab begins.
The business logic and the clinical logic overlap here. If a patient cannot get to rehab, the most evidence-based program in the world still fails at the point of implementation. Virtual care changes that barrier into a variable the care team can manage.
What this partnership can and cannot prove yet
The announcement is ambitious, but it is still a partnership announcement rather than a controlled outcomes study. The collaboration promises education, demonstration projects, and joint research pilots, yet it does not present comparative data showing superiority over standard rehabilitation, nor does it provide new sample sizes, endpoint results, or long-term durability findings. Those answers will have to come from the pilots, conference discussions, and any future reports tied to the national rollout.
For now, the most concrete signal is strategic: ACLM is aligning one of its lifestyle medicine programs with a virtual care company that already serves patients through monitored home rehabilitation. In chronic disease care, access is often the first obstacle and adherence the second. This partnership is built to address both, but the real test will be whether broader access translates into better completion, fewer readmissions, and care that patients can actually sustain beyond the first few weeks at home.